Resident Investigators

Jillian Bonaroti, MD                                                                                                         Surgery, PGY-4

Medical School: Thomas Jefferson University
Mentors:
Timothy Billiar, MD, and Matthew Neal, MD

Dr. Bonaroti’s research seeks to characterize the transcriptome of megakaryocytes isolated from bone marrow of trauma patients. She hypothesizes that trauma will induce transcriptional changes in the megakaryocyte and may induce previously unidentified subpopulations of megakaryocytes. Additionally, she suggests that these transcriptional changes lead to alteration in the transcriptome of the platelet, causing the known alterations in platelet function following trauma. Her project will be part of larger collaboration to study human samples from deceased trauma patients for which she will gather blood, bone marrow, and tissue samples from these patients from the CORE facility. After processing BM samples and performing flow cytometry to sort out megakaryocytes, Dr. Bonaroti will use bulk RNA-seq and single cell RNA sequencing to characterize the megakaryocyte transcriptome.

 

Tiffany Brazile, MD                                                                                                        Medicine, PGY-3

Medical School: Geisel School of Medicine, Dartmouth College
Mentors:
Samir Saba, MD, and Suresh Mulukutla, MD

Dr. Brazile is conducting a retrospective cohort study to evaluate the presence of an “obesity paradox” in cardiomyopathy patients with respect to all-cause mortality, hospitalizations, and specifically cardiac hospitalizations. Results will be stratified by ejection fraction to determine whether the protective effect of having an elevated BMI is present regardless of degree of left ventricular dysfunction. This study will also evaluate the effect of ICD implantation on patient mortality as stratified by BMI and ejection fraction.  Dr. Brazile is also currently engaged in a retrospective study of patients from the UPMC multi-site dataset to evaluate high-risk patients with diagnosis of STEMI based on diagnostic codes who underwent primary PCI.